1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Neurodegenerativas: desarrollo de terapias

Enfermedades Neurodegenerativas: desarrollo de terapias

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

    Prospects for cannabinoid therapies in basal ganglia disorders

    BRITISH JOURNAL OF PHARMACOLOGY . 163(7, SI): 1365-1378. Nº de citas: 96

    [doi:10.1111/j.1476-5381.2011.01365.x]

  • García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J.

    Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease

    BRITISH JOURNAL OF PHARMACOLOGY . 163(7, SI): 1495-1506. Nº de citas: 174

    [doi:10.1111/j.1476-5381.2011.01278.x]

  • Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A.

    Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism

    ANTIOXIDANTS & REDOX SIGNALING . 14(12): 2347-2360. Nº de citas: 282

    [doi:10.1089/ars.2010.3731]

  • Casarejos MJ, Solano RM, Gómez A, Perucho J, de Yébenes JG, Mena MA.

    The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells

    NEUROCHEMISTRY INTERNATIONAL . 58(4): 512-520. Nº de citas: 100

    [doi:10.1016/j.neuint.2011.01.008]

  • Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M.

    Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain . 134(1): 119-136. Nº de citas: 156

    [doi:10.1093/brain/awq278]

  • García-Fernández N, Pérez-Valdivieso JR, Bes-Rastrollo M, Vives M, Lavilla J, Herreros J, Monedero P.

    Timing of Renal Replacement Therapy after Cardiac Surgery: A Retrospective Multicenter Spanish Cohort Study

    BLOOD PURIFICATION . 32(2): 104-111. Nº de citas: 39

    [doi:10.1159/000324195]

  • Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, Solano RM, Gómez A, Perucho J, Cuervo AM, García de Yébenes J, Mena MA.

    Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation

    NEUROBIOLOGY OF DISEASE . 39(3): 423-438. Nº de citas: 254

    [doi:10.1016/j.nbd.2010.05.014]

  • Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A.

    Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1

    Plos One . 5(7): . Nº de citas: 120

    [doi:10.1371/journal.pone.0011838]

  • Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernández-Ruiz J, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S.

    A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice

    Plos One . 5(7): . Nº de citas: 104

    [doi:10.1371/journal.pone.0011464]

  • Fernández-Ruiz J, Hernández M, Ramos JA.

    Cannabinoid-Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders

    CNS NEUROSCIENCE & THERAPEUTICS . 16(3): 72-91. Nº de citas: 133

    [doi:10.1111/j.1755-5949.2010.00144.x]

  • Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E.

    The endocannabinoid system as a target for the treatment of neuronal damage

    EXPERT OPINION ON THERAPEUTIC TARGETS . 14(4): 387-404. Nº de citas: 76

    [doi:10.1517/14728221003709792]

  • Sagar DR, Jhaveri MD, Richardson D, Gray RA, de Lago E, Fernández-Ruiz J, Barrett DA, Kendall DA, Chapman V.

    Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain

    EUROPEAN JOURNAL OF NEUROSCIENCE . 31(8): 1414-1422. Nº de citas: 28

    [doi:10.1111/j.1460-9568.2010.07162.x]

  • Perucho J, Rubio I, Casarejos MJ, Gomez A, Rodriguez-Navarro JA, Solano RM, De Yébenes JG, Mena MA.

    Anesthesia with Isoflurane Increases Amyloid Pathology in Mice Models of Alzheimer's Disease

    JOURNAL OF ALZHEIMERS DISEASE . 19(4): 1245-1257. Nº de citas: 79

    [doi:10.3233/JAD-2010-1318]

  • Mena MÁ, Perucho J, Rubio I, de Yébenes JG.

    Studies in Animal Models of the Effects of Anesthetics on Behavior, Biochemistry, and Neuronal Cell Death

    JOURNAL OF ALZHEIMERS DISEASE . 22(3): 43-48. Nº de citas: 18

    [doi:10.3233/JAD-2010-100822]

  • Perucho J, Casarejos MJ, Rubio I, Rodriguez-Navarro JA, Gómez A, Ampuero I, Rodal I, Solano RM, Carro E, García de Yébenes J, Mena MA.

    The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice

    EXPERIMENTAL NEUROLOGY . 221(1): 54-67. Nº de citas: 15

    [doi:10.1016/j.expneurol.2009.09.029]

  • Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I.

    Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain . 132(11): 3152-3164. Nº de citas: 313

    [doi:10.1093/brain/awp239]

  • de Lago E, Gómez-Ruiz M, Moreno-Martet M, Fernández-Ruiz J.

    Cannabinoids, multiple sclerosis and neuroprotection.

    EXPERT REVIEW OF CLINICAL PHARMACOLOGY . 2(6): 645-660.

    [doi:10.1586/ecp.09.42]

  • Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J.

    Cannabinoid CB2 Receptor Agonists Protect the Striatum Against Malonate Toxicity: Relevance for Huntington's Disease

    Glia . 57(11): 1154-1167. Nº de citas: 151

    [doi:10.1002/glia.20838]